
Early clinical studies of TMC125, a new non-nucleoside reverse transcriptase inhibitor, indicate the drug is extremely potent, with an average reduction in HIV viral load of 99% after one week of treatment.
Placebos, Pyridazines, Pyrimidines, Treatment Outcome, Double-Blind Method, Anti-HIV Agents, Nitriles, Humans, Reverse Transcriptase Inhibitors, Drug Resistance, Microbial, HIV Infections, Controlled Clinical Trials as Topic, Viral Load
Placebos, Pyridazines, Pyrimidines, Treatment Outcome, Double-Blind Method, Anti-HIV Agents, Nitriles, Humans, Reverse Transcriptase Inhibitors, Drug Resistance, Microbial, HIV Infections, Controlled Clinical Trials as Topic, Viral Load
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
